Immunological effects of chemotherapy in spontaneous breast cancers

OncoImmunology

Volumn 2, Issue 12, 2013, Pages

  Kroemer, Guido ^a,b,c,d,e   Galluzzi, Lorenzo ^a,b,f   Zitvogel, Laurence ^f,g,h,i  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c Institut Gustave Roussy   (France)

^d Metabolomics Platform   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g University Paris XI   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

Author keywords

HER2; MMTV NeuT mice; Oncogene addiction; p53; Trastuzumab

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; N METHYLTRYPTOPHAN; OXALIPLATIN; PACLITAXEL; TRICIRIBINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; GENE; HER2 GENE; HUMAN; IMMUNOSURVEILLANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACOGENETICS; RAG2 GENE; TRP53 GENE; TUMOR IMMUNITY;

EID: 84894527433     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27158     Document Type: Article

References (29)

1. Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med 2012; 18:344-6, author reply 346; http://dx.doi.org/10.1038/nm.2652
2. Ciampricotti M, Vrijland K, Hau CS, Pemovska T, Doornebal CW, Speksnijder EN, Wartha K, Jonkers J, de Visser KE. Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J Pathol 2011; 224:56-66; http://dx.doi.org/10.1002/path.2837
3. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/ onci.23510
4. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008
5. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; http:// dx.doi.org/10.1016/j.immuni.2013.06.014
6. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; http://dx.doi.org/10.1016/j.immuni.2013.03.003
7. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; http://dx.doi.org/10.1126/science.1224922
8. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; http://dx.doi.org/10.1126/science.1208347
9. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; http://dx.doi.org/10.1038/ nrclinonc.2010.223
10. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; http://dx.doi.org/10.1038/ nrd3626
11. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; http://dx.doi.org/10.1172/JCI35180
12. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; http://dx.doi.org/10.1038/nm1196
13. Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57:907-12; http://dx.doi.org/10.1007/s00262-007-0414-0
14. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464:302-5; http://dx.doi.org/10.1038/nature08782
15. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogenedriven breast cancer and enhances radiotherapy. J Exp Med 2013; 210:2435-66; http:// dx.doi.org/10.1084/jem.20130762
16. Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller JB, Tripp CH, Stoitzner P, et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol 2013; 43:2718-29; http://dx.doi.org/10.1002/ eji.201242505
17. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; http://dx.doi.org/10.1016/j. ccr.2010.06.014
18. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011; 108:7142-7; http://dx.doi.org/10.1073/ pnas.1016569108
19. Mavilio D, Galluzzi L, Lugli E. Novel multifunctional antibody approved for the treatment of breast cancer. Oncoimmunology 2013; 2:e24567; http://dx.doi.org/10.4161/ onci.24567
20. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; http://dx.doi.org/10.4161/ onci.22789
21. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; http://dx.doi.org/10.4161/onci.1.1.17938
22. Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 2012; 72:4417-28; http://dx.doi.org/10.1158/0008-5472.CAN-12-1339-T
23. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013; 2:e25396; http://dx.doi.org/10.4161/ onci.25396
24. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852-63; http://dx.doi.org/10.1038/nri3108
25. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
26. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; http:// dx.doi.org/10.1200/JCO.2009.23.7370
27. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2013; 2:e24720; http://dx.doi.org/10.4161/onci.24720
28. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-7; http://dx.doi.org/10.1200/JCO.2011.41.0902
29. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; http://dx.doi.org/10.4161/ onci.22009